Tower Research Capital (TRC)’s Decibel Therapeutics, Inc. Common Stock DBTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio DBTX Stock Details DBTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,867	Closed	-$11K	–	6396
2023 Q2	$11K	Sell	2,867 -2,226	-44%	-$8.17K	﹤0.01%	4023
2023 Q1	$15K	Sell	5,093 -4,885	-49%	-$16.9K	﹤0.01%	3846
2022 Q4	$20K	Sell	9,978 -1,720	-15%	-$5.24K	﹤0.01%	3159
2022 Q3	$41K	Buy	11,698 +11,082	+1,799%	+$50.4K	﹤0.01%	3341
2022 Q2	$2K	Sell	616 -78	-11%	-$184	﹤0.01%	5654
2022 Q1	$2K	Sell	694 -715	-51%	-$2.74K	﹤0.01%	5659
2021 Q4	$7K	Buy	+1,409	New	+$9.7K	﹤0.01%	4970
2021 Q2	–	Sell	-1,217	Closed	-$14K	–	6006
2021 Q1	$14K	Buy	+1,217	New	+$19.1K	﹤0.01%	4176

Other funds holding DBTX

ACA

Atlas Capital Advisors Jackson, Wyoming $875M AUM

Tower Research Capital (TRC)'s DBTX Position: Q3 2023 in Review

Tower Research Capital (TRC) sold out of Decibel Therapeutics, Inc. Common Stock (DBTX) in Q3 2023, closing a stake of 2,867 shares — an estimated $11K sold.

Tower Research Capital (TRC) first reported a position in DBTX in Q1 2021 and held it in 8 quarters. The position peaked at $41K in Q3 2022. 1 fund tracked by Wall St. Rank holds DBTX as of Q3 2023.

Tower Research Capital (TRC) reported no remaining Decibel Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Tower Research Capital (TRC) sold 2,867 Decibel Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $11K.
Tower Research Capital (TRC) first reported a position in Decibel Therapeutics, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
Tower Research Capital (TRC)'s Decibel Therapeutics, Inc. Common Stock position peaked at $41K in Q3 2022.
1 fund tracked by Wall St. Rank held Decibel Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2023, filed 14 Nov 2023.